Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | HSD11B1 known ✓ | P28845 | 1/20 | 0.34 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.33 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.33 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL140205 | 0.98 | ALDH1A1 (0.40) | ALDH1A1HTTLMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL8126712 | 0.92 | ALDH1A1 (0.50) | ALDH1A1HTTLMNAMEN1KMT2A | |
| SCHEMBL11454156 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL29032347 | 0.80 | ALDH1A1 (0.46) | ALDH1A1HTTLMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL641317 | 0.78 | ALDH1A1 (0.58) | ALDH1A1HTTLMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL693967 | 0.77 | EPHX2 (0.43) | CYP1A2TDP1RIPK1SMN1; SMN2 | |
| SCHEMBL27311104 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HTTLMNAMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL490234 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL4788803 | 0.76 | SMN1; SMN2 (0.57) | ALDH1A1HTTMEN1KMT2ATDP1 | |
| Hydrochloric Acid SCHEMBL14311961 | 0.76 | SMN1; SMN2 (0.57) | ALDH1A1HTTMEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104860888-A | Alcaftadine intermediate and synthetic method for alcaftadine | NANJING HUAWE MEDICAL TECHNOLOGY DEV CO LTD | 2015-08-26 | — | — | CN | claimed |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2026-03-26 | — | — | US | disclosed |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4583977-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-07-16 | — | — | EP | disclosed |
| US-20250206755-A1 | ANTIMICROBIAL AGENTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2025-06-26 | — | — | US | disclosed |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2024-08-29 | — | — | US | disclosed |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p. A. (IT) | 2024-06-27 | — | — | US | disclosed |
| CN-118239953-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2024-06-25 | — | — | CN | disclosed |
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2024-05-16 | — | — | US | disclosed |
| WO-2024052512-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | WO | disclosed |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | ELI LILLY AND COMPANY | 2005-10-06 | — | — | US | disclosed |
| EP-1492786-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1028961-B1 | PLEUROMUTILIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-29 | — | — | EP | disclosed |
| EP-1452534-A1 | PLEUROMUTLIN DERIVATIVES AS ANTIMICROBIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-09-01 | — | — | EP | disclosed |
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-22 | — | — | US | disclosed |
| WO-2003084949-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| EP-1347972-A1 | PYRAZOLO 3,4-C]PYRIDINES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002050073-A1 | PYRAZOLO[3,4-C]PYRIDINES AS GSK-3 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-6281226-B1 | Pleuromutilin derivatives as antimicrobials | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-28 | — | — | US | disclosed |
| US-4045445-A | 11-(4-Piperidyl)dibenzo-diazepines | AMERICAN CYANAMID COMPANY (US) | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD2 | HRH3 2478/4885HSD11B1 806/4885SCN1A 2939/4885 |
| US-20040077681-A1 | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors | GSK3B, GSK3A, GSKIP | HRH3 1288/4885HSD11B1 483/4885SCN1A 1547/4885 |
| US-20260085077-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK1, JAK3 | HRH3 151/4885HSD11B1 2192/4885SCN1A 1253/4885 |
| US-20240287086-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR3, FGFR1, FGFR2 | HRH3 3005/4885HSD11B1 2638/4885SCN1A 4435/4885 |
| US-20240209001-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | TYK2, JAK3, JAK1 | HRH3 405/4885HSD11B1 2694/4885SCN1A 3384/4885 |
| US-12552804-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | HRH3 1680/4885HSD11B1 231/4885SCN1A 1076/4885 |
| US-20250206755-A1 | ANTIMICROBIAL AGENTS | CFTR, MRPL21, ARG1 | HRH3 656/4885HSD11B1 3025/4885SCN1A 4128/4885 |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | HTR1F, HTR1A, HTR1E | HRH3 28/4885HSD11B1 3137/4885SCN1A 312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.